Home > Publications Database > Patient-reported, health economic and psychosocial outcomes in patients with Friedreich ataxia (PROFA): protocol of an observational study using momentary data assessments via mobile health app. > print

001     259692
005     20231120155352.0
024 7 _ |a 10.1136/bmjopen-2023-075736
|2 doi
024 7 _ |a pmid:37527887
|2 pmid
024 7 _ |a pmc:PMC10394552
|2 pmc
024 7 _ |a altmetric:152617868
|2 altmetric
037 _ _ |a DZNE-2023-00764
041 _ _ |a English
082 _ _ |a 610
100 1 _ |a Buchholz, Maresa
|0 P:(DE-2719)9002138
|b 0
|e First author
|u dzne
245 _ _ |a Patient-reported, health economic and psychosocial outcomes in patients with Friedreich ataxia (PROFA): protocol of an observational study using momentary data assessments via mobile health app.
260 _ _ |a London
|c 2023
|b BMJ Publishing Group
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1692712309_2158
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
520 _ _ |a Friedreich ataxia (FA) is the most common hereditary ataxia in Europe, characterised by progressively worsening movement and speech impairments with a typical onset before the age of 25 years. The symptoms affect the patients' health-related quality of life (HRQoL) and psychosocial health. FA leads to an increasing need for care, associated with an economic burden. Little is known about the impact of FA on daily lives and HRQoL. To fill that gap, we will assess patient-reported, psychosocial and economic outcomes using momentary data assessment via a mobile health application (app).The PROFA Study is a prospective observational study. Patients with FA (n=200) will be recruited at six European study centres (Germany, France and Austria). We will interview patients at baseline in the study centre and subsequently assess the patients' health at home via mobile health app. Patients will self-report ataxia severity, HRQoL, speech and hearing disabilities, coping strategies and well-being, health services usage, adverse health events and productivity losses due to informal care on a daily to monthly basis on the app for 6 months. Our study aims to (1) validate measurements of HRQoL and psychosocial health, (2) assess the usability of the mobile health app, and (3) use descriptive and multivariate statistics to analyse patient-reported and economic outcomes and the interaction effects between these outcomes. Insights into the app's usability could be used for future studies using momentary data assessments to measure outcomes of patients with FA.Ethical approval has been obtained from the Ethics Committee of the University Medicine of Greifswald, (BB096/22a, 26 October 2022) and from all local ethics committees of the participating study sites. Findings of the study will be published in peer-reviewed journals, presented at relevant international/national congresses and disseminated to German and French Patient Advocacy Organizations.ClinicalTrials.gov Registry (NCT05943002); Pre-results.
536 _ _ |a 353 - Clinical and Health Care Research (POF4-353)
|0 G:(DE-HGF)POF4-353
|c POF4-353
|f POF IV
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed, , Journals: pub.dzne.de
650 _ 7 |a Friedreich ataxia
|2 Other
650 _ 7 |a Rare diseases
|2 Other
650 _ 7 |a health and informal care
|2 Other
650 _ 7 |a health economics
|2 Other
650 _ 7 |a m-health app assessment
|2 Other
650 _ 7 |a patient-reported outcomes
|2 Other
650 _ 7 |a speech and hearing disabilities
|2 Other
650 _ 2 |a Humans
|2 MeSH
650 _ 2 |a Adult
|2 MeSH
650 _ 2 |a Friedreich Ataxia
|2 MeSH
650 _ 2 |a Quality of Life
|2 MeSH
650 _ 2 |a Mobile Applications
|2 MeSH
650 _ 2 |a Telemedicine: methods
|2 MeSH
650 _ 2 |a Patient Reported Outcome Measures
|2 MeSH
650 _ 2 |a Observational Studies as Topic
|2 MeSH
700 1 _ |a Weber, Niklas
|0 P:(DE-2719)9001915
|b 1
|u dzne
700 1 _ |a Borel, Stephanie
|b 2
700 1 _ |a Sayah, Sabrina
|b 3
700 1 _ |a Xie, Feng
|0 0000-0003-3454-6266
|b 4
700 1 _ |a Schulz, Jörg B
|b 5
700 1 _ |a Reetz, Kathrin
|b 6
700 1 _ |a Boesch, Sylvia
|b 7
700 1 _ |a Klopstock, Thomas
|0 P:(DE-2719)2810704
|b 8
|u dzne
700 1 _ |a Karin, Ivan
|b 9
700 1 _ |a Schöls, Ludger
|0 P:(DE-2719)2810795
|b 10
|u dzne
700 1 _ |a Grobe-Einsler, Marcus
|0 P:(DE-2719)9001510
|b 11
|u dzne
700 1 _ |a Klockgether, Thomas
|0 P:(DE-2719)2810314
|b 12
|u dzne
700 1 _ |a Davies, Elin Haf
|b 13
700 1 _ |a Schmeder, Madeleine
|b 14
700 1 _ |a Nadke, Andreas
|b 15
700 1 _ |a Michalowsky, Bernhard
|0 P:(DE-2719)2810763
|b 16
|e Last author
|u dzne
773 _ _ |a 10.1136/bmjopen-2023-075736
|g Vol. 13, no. 8, p. e075736 -
|0 PERI:(DE-600)2599832-8
|n 8
|p e075736
|t BMJ open
|v 13
|y 2023
|x 2044-6055
856 4 _ |y OpenAccess
|u https://pub.dzne.de/record/259692/files/DZNE-2023-00764.pdf
856 4 _ |y OpenAccess
|x pdfa
|u https://pub.dzne.de/record/259692/files/DZNE-2023-00764.pdf?subformat=pdfa
909 C O |o oai:pub.dzne.de:259692
|p openaire
|p open_access
|p VDB
|p driver
|p dnbdelivery
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 0
|6 P:(DE-2719)9002138
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 1
|6 P:(DE-2719)9001915
910 1 _ |a External Institute
|0 I:(DE-HGF)0
|k Extern
|b 8
|6 P:(DE-2719)2810704
910 1 _ |a External Institute
|0 I:(DE-HGF)0
|k Extern
|b 10
|6 P:(DE-2719)2810795
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 11
|6 P:(DE-2719)9001510
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 12
|6 P:(DE-2719)2810314
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 16
|6 P:(DE-2719)2810763
913 1 _ |a DE-HGF
|b Gesundheit
|l Neurodegenerative Diseases
|1 G:(DE-HGF)POF4-350
|0 G:(DE-HGF)POF4-353
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-300
|4 G:(DE-HGF)POF
|v Clinical and Health Care Research
|x 0
914 1 _ |y 2023
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0160
|2 StatID
|b Essential Science Indicators
|d 2022-11-12
915 _ _ |a Creative Commons Attribution-NonCommercial CC BY-NC 4.0
|0 LIC:(DE-HGF)CCBYNC4
|2 HGFVOC
915 _ _ |a WoS
|0 StatID:(DE-HGF)0113
|2 StatID
|b Science Citation Index Expanded
|d 2022-11-12
915 _ _ |a Fees
|0 StatID:(DE-HGF)0700
|2 StatID
|d 2022-11-12
915 _ _ |a OpenAccess
|0 StatID:(DE-HGF)0510
|2 StatID
915 _ _ |a Article Processing Charges
|0 StatID:(DE-HGF)0561
|2 StatID
|d 2022-11-12
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0501
|2 StatID
|b DOAJ Seal
|d 2023-05-02T08:46:44Z
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0500
|2 StatID
|b DOAJ
|d 2023-05-02T08:46:44Z
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b DOAJ : Open peer review
|d 2023-05-02T08:46:44Z
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b BMJ OPEN : 2022
|d 2023-10-26
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2023-10-26
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2023-10-26
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0320
|2 StatID
|b PubMed Central
|d 2023-10-26
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2023-10-26
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2023-10-26
915 _ _ |a IF < 5
|0 StatID:(DE-HGF)9900
|2 StatID
|d 2023-10-26
920 1 _ |0 I:(DE-2719)1510600
|k AG Hoffmann
|l Translational Health Care Research
|x 0
920 1 _ |0 I:(DE-2719)1510800
|k AG Thyrian
|l Interventional Health Care Research (IHCR)
|x 1
920 1 _ |0 I:(DE-2719)1011001
|k AG Klockgether
|l Patient Studies
|x 2
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a UNRESTRICTED
980 _ _ |a I:(DE-2719)1510600
980 _ _ |a I:(DE-2719)1510800
980 _ _ |a I:(DE-2719)1011001
980 1 _ |a FullTexts

LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21